Weight-loss drug forecasts sales jump to $150bn as supply grows

Most insurers do not cover the new therapies with low co-payments, but an unprecedented percentage of people are paying themselves or with coupons from drug manufacturers.

Supplies of both Novo's Wegovy remain constrained.

As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150bn (€137bn) by the early 2030s.

A year ago, top sales estimates were in the $100bn range.